Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma. Furtner, J., Schopf, V., Seystahl, K., Le Rhun, E., Ruda, R., Roelcke, U., Koeppen, S., Berghoff, A. S., Marosi, C., Clement, P., Faedi, M., Watts, C., Wick, W., Soffietti, R., Weller, M., & Preusser, M. Neuro Oncol, 18(3):401–7, March, 2016.
Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma [link]Paper  doi  abstract   bibtex   
BACKGROUND: The efficacy of systemic antineoplastic therapy on recurrent World Health Organization (WHO) grades II and III meningiomas is unclear. METHODS: We performed a retrospective multicenter analysis of serial cranial MRI in patients with recurrent WHO II and III meningiomas treated with antineoplastic systemic therapies. Growth rates for tumor volume and diameter, as well as change rates for edema size, were calculated for all lesions. RESULTS: We identified a total of 34 patients (23 atypical, 11 anaplastic meningiomas) with a total of 57 meningioma lesions who had been treated at 6 European institutions. Systemic therapies included bevacizumab, cytotoxic chemotherapy, somatostatin analogues, and tyrosine kinase inhibitors. Overall, tumor growth rates decreased during systemic therapy by 51% for tumor diameter and 14% for tumor volume growth rates compared with the period before initiation of systemic therapy. The most pronounced decrease in meningioma growth rates during systemic therapy was evident in patients treated with bevacizumab, with a reduction of 80% in diameter and 59% in volume growth. Furthermore, a decrease in size of peritumoral edema after initiation of systemic therapy was exclusively observed in patients treated with bevacizumab (-107%). CONCLUSIONS: Our data indicate that systemic therapy may inhibit growth of recurrent WHO grades II and III meningiomas to some extent. In our small cohort, bevacizumab had the most pronounced inhibitory effect on tumor growth, as well as some anti-edematous activity. Prospective studies are needed to better define the role of medical therapies in this tumor type.
@article{furtner_kinetics_2016,
	title = {Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent {WHO} grade {II} or {III} meningioma},
	volume = {18},
	issn = {1523-5866 (Electronic) 1522-8517 (Linking)},
	url = {http://www.ncbi.nlm.nih.gov/pubmed/26354929},
	doi = {10.1093/neuonc/nov183},
	abstract = {BACKGROUND: The efficacy of systemic antineoplastic therapy on recurrent World Health Organization (WHO) grades II and III meningiomas is unclear. METHODS: We performed a retrospective multicenter analysis of serial cranial MRI in patients with recurrent WHO II and III meningiomas treated with antineoplastic systemic therapies. Growth rates for tumor volume and diameter, as well as change rates for edema size, were calculated for all lesions. RESULTS: We identified a total of 34 patients (23 atypical, 11 anaplastic meningiomas) with a total of 57 meningioma lesions who had been treated at 6 European institutions. Systemic therapies included bevacizumab, cytotoxic chemotherapy, somatostatin analogues, and tyrosine kinase inhibitors. Overall, tumor growth rates decreased during systemic therapy by 51\% for tumor diameter and 14\% for tumor volume growth rates compared with the period before initiation of systemic therapy. The most pronounced decrease in meningioma growth rates during systemic therapy was evident in patients treated with bevacizumab, with a reduction of 80\% in diameter and 59\% in volume growth. Furthermore, a decrease in size of peritumoral edema after initiation of systemic therapy was exclusively observed in patients treated with bevacizumab (-107\%). CONCLUSIONS: Our data indicate that systemic therapy may inhibit growth of recurrent WHO grades II and III meningiomas to some extent. In our small cohort, bevacizumab had the most pronounced inhibitory effect on tumor growth, as well as some anti-edematous activity. Prospective studies are needed to better define the role of medical therapies in this tumor type.},
	number = {3},
	journal = {Neuro Oncol},
	author = {Furtner, J. and Schopf, V. and Seystahl, K. and Le Rhun, E. and Ruda, R. and Roelcke, U. and Koeppen, S. and Berghoff, A. S. and Marosi, C. and Clement, P. and Faedi, M. and Watts, C. and Wick, W. and Soffietti, R. and Weller, M. and Preusser, M.},
	month = mar,
	year = {2016},
	keywords = {Adult, Aged, Angiogenesis Inhibitors/therapeutic use, Bevacizumab/therapeutic use, Brain Edema/*etiology, Brain Neoplasms/complications/*pathology, Female, Humans, Kinetics, Male, Meningeal Neoplasms/classification/complications/*pathology, Meningioma/classification/complications/*pathology, Middle Aged, Retrospective Studies},
	pages = {401--7},
}
Downloads: 0